OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PEPG$1.6559

PepGen Inc

Biotechnology & Medical ResearchVerified

PepGen Inc operates with a strong liquidity position, as evidenced by a current ratio of 7.45 and cash and equivalents of $66.09 million, which significantly exceeds its total liabilities of $38.47 million. The company's price-to-book ratio of 0.74 indicates that its market value is trading below its book value, suggesting potential undervaluation. However, the company's liquidity is not supported by positive operating cash flow, which was negative at -$38.89 million in the latest period. Profitability metrics for PepGen are negative, with a net income of -$28.34 million and an operating income of -$30.43 million. The company's return on equity (ROE) is -18.28%, and its return on assets (ROA) is -14.64%, both of which are significantly below the industry median for biotechnology firms. These figures indicate that the company is not generating returns for shareholders and is underperforming in asset utilization. PepGen's revenue is not disclosed in the provided data, and no specific geographic or segment breakdown is available. However, the absence of long-term debt and the low dilution risk suggest that the company is not heavily reliant on external financing or equity issuance to fund operations. This may indicate a more stable capital structure, but it also suggests limited growth through debt or equity financing. Looking ahead, the company's growth trajectory is uncertain. The latest financial data shows a negative free cash flow of -$27.97 million and a capital expenditure of -$84,000, indicating that the company is not investing in new projects or expanding its operations. Analysts have provided a wide range of price targets, from $3.00 to $20.00, with a mean of $10.14 and a median of $10.00, suggesting a high degree of uncertainty about the company's future performance. The risk assessment for PepGen indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative operating and net income, along with its negative cash flows, suggest that it is not currently generating sustainable earnings. The absence of long-term debt and the low dilution risk may provide some stability, but the company's financial performance remains a concern. Recent events and filings do not provide specific details about the company's operations or strategic direction. The lack of disclosed revenue segments and geographic exposure makes it difficult to assess the company's market position and diversification. The company's reliance on cash and equivalents to fund operations may limit its ability to invest in growth opportunities or respond to market changes.

30-day price · PEPG-0.09 (-5.1%)
Low$1.32High$2.08Close$1.68As of13 May, 00:00 UTC
Profile
CompanyPepGen Inc
TickerPEPG.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. PepGen Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing innovative diagnostic solutions to support patient care and treatment decisions.

Classification. PepGen is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

PepGen Inc operates with a strong liquidity position, as evidenced by a current ratio of 7.45 and cash and equivalents of $66.09 million, which significantly exceeds its total liabilities of $38.47 million. The company's price-to-book ratio of 0.74 indicates that its market value is trading below its book value, suggesting potential undervaluation. However, the company's liquidity is not supported by positive operating cash flow, which was negative at -$38.89 million in the latest period. Profitability metrics for PepGen are negative, with a net income of -$28.34 million and an operating income of -$30.43 million. The company's return on equity (ROE) is -18.28%, and its return on assets (ROA) is -14.64%, both of which are significantly below the industry median for biotechnology firms. These figures indicate that the company is not generating returns for shareholders and is underperforming in asset utilization. PepGen's revenue is not disclosed in the provided data, and no specific geographic or segment breakdown is available. However, the absence of long-term debt and the low dilution risk suggest that the company is not heavily reliant on external financing or equity issuance to fund operations. This may indicate a more stable capital structure, but it also suggests limited growth through debt or equity financing. Looking ahead, the company's growth trajectory is uncertain. The latest financial data shows a negative free cash flow of -$27.97 million and a capital expenditure of -$84,000, indicating that the company is not investing in new projects or expanding its operations. Analysts have provided a wide range of price targets, from $3.00 to $20.00, with a mean of $10.14 and a median of $10.00, suggesting a high degree of uncertainty about the company's future performance. The risk assessment for PepGen indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative operating and net income, along with its negative cash flows, suggest that it is not currently generating sustainable earnings. The absence of long-term debt and the low dilution risk may provide some stability, but the company's financial performance remains a concern. Recent events and filings do not provide specific details about the company's operations or strategic direction. The lack of disclosed revenue segments and geographic exposure makes it difficult to assess the company's market position and diversification. The company's reliance on cash and equivalents to fund operations may limit its ability to invest in growth opportunities or respond to market changes.
Key takeaways
  • PepGen Inc has a strong liquidity position with a current ratio of 7.45 and $66.09 million in cash and equivalents.
  • The company is currently unprofitable, with a net loss of $28.34 million and a negative ROE of -18.28%.
  • PepGen's market price of $1.65 is significantly below its book value, as indicated by a price-to-book ratio of 0.74.
  • Analysts have provided a wide range of price targets, from $3.00 to $20.00, with a mean of $10.14, indicating uncertainty about the company's future performance.
  • The company has no long-term debt and a low dilution risk, suggesting a stable capital structure but limited growth through financing.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income-$30.4M
Net income-$28.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$38.9M
CapEx-$84.0k
Free cash flow-$28.0M
Total assets$193.5M
Total liabilities$38.5M
Total equity$155.0M
Cash & equivalents$66.1M
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$27.1M-$27.3M-$27.6M
FY-3-$68.3M-$69.1M-$72.4M
FY-2-$84.8M-$78.6M-$80.0M
FY-1-$97.7M-$90.0M-$89.0M
FY0-$93.6M-$89.7M-$88.5M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$143.6M$133.1M$132.9M
FY-3$217.4M$179.6M$181.8M
FY-2$143.1M$108.4M$80.8M
FY-1$150.9M$118.6M$49.4M
FY0$173.9M$147.4M$60.5M
PeriodOCFCapExFCFSBC
FY-4-$22.6M-$500.0k-$27.6M
FY-3-$59.3M-$3.8M-$72.4M
FY-2-$69.0M-$2.6M-$80.0M
FY-1-$82.4M-$497.0k-$89.0M
FY0-$81.6M-$264.0k-$88.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7-$30.4M-$28.3M-$28.0M
FQ-6-$23.2M-$21.4M-$21.2M
FQ-5-$24.3M-$22.2M-$22.1M
FQ-4-$31.3M-$30.2M-$29.9M
FQ-3-$23.9M-$23.1M-$22.8M
FQ-2-$18.7M-$18.0M-$17.8M
FQ-1-$19.7M-$18.3M-$18.0M
FQ0-$18.9M-$17.8M-$17.4M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$193.5M$155.0M$66.1M
FQ-6$170.2M$137.5M$42.3M
FQ-5$150.9M$118.6M$49.4M
FQ-4$127.4M$91.8M$43.6M
FQ-3$102.2M$71.2M$35.1M
FQ-2$190.1M$163.1M$142.8M
FQ-1$173.9M$147.4M$60.5M
FQ0$156.3M$134.0M$42.1M
PeriodOCFCapExFCFSBC
FQ-7-$38.9M-$84.0k-$28.0M
FQ-6-$62.9M-$269.0k-$21.2M
FQ-5-$82.4M-$497.0k-$22.1M
FQ-4-$22.9M-$125.0k-$29.9M
FQ-3-$46.5M-$168.0k-$22.8M
FQ-2-$65.8M-$265.0k-$17.8M
FQ-1-$81.6M-$264.0k-$18.0M
FQ0-$18.4M$0.00-$17.4M
Valuation
Market price$1.65
Market cap$114.1M
Enterprise value$48.0M
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B0.7
P/Tangible book0.7
Tangible book$155.0M
Net cash$66.1M
Current ratio7.5
Debt/Equity0.0
ROA-14.6%
ROE-18.3%
Cash conversion1.4%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricPEPGActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Observations
IR observations
Mean price target10.14 USD
Median price target10.00 USD
High price target20.00 USD
Low price target3.00 USD
Mean recommendation1.57 (1=strong buy, 5=strong sell)
Strong-buy count5.00
Buy count1.00
Hold count0.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate-1.21 USD
Last actual EPS-2.12 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-17 01:32 UTC#3ed1a7d3
Market quoteclose USD 1.79 · shares 0.07B diluted
no public URL
2026-05-17 01:32 UTC#1657f920
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 23:01 UTCJob: 4fdf183f